


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: M. REDMON et al.

Application No.: 09/049,227

Filed: March 27, 1998

For: STABLE DOSAGE FORMS OF
FLUOXETINE AND ITS
ENANTIOMERS



Group Art Unit: 1654

Examiner: C. Delacroix-Muirhei

Attorney Docket No.: 4821-304

#14/B
(14)
JRL
3/31/00

AMENDMENT UNDER 37 C.F.R. § 1.116

Box AF

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Final Office Action mailed September 23, 1999, Applicants submit herewith the following amendments and remarks for entry into the record and consideration by the Examiner. Applicants also submit concurrently herewith: a) a Notice of Appeal, with provision for the required fee; and b) a Petition for Extension of Time, with provision for the required fee, to extend the time for response from December 23, 1999 for an additional three months to and including March 23, 2000.

Applicants respectfully request reconsideration of the pending claims and allowance thereof.

IN THE CLAIMS:

Please amend the claims as follows:

13. (Amended) A chemically stable compressed tablet free of lactose which comprises racemic fluoxetine, an optically pure enantiomer of fluoxetine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein said tablet does not dissolve in less than three minutes when subjected to the DISSOLUTION TEST.